Editors' (re)View

Welcome to Editors' (re)View, our editors’ weekly takes on things going on in the pharma world that deserve some extra consideration.

Articles

Editors' (re)View: Greetings from Portugal; The future of weight loss drugs

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 14

Editors' (re)View: FDA second chances; FTC takes aim at PBMs

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 8

Editors' (re)View: BARDA bucks for MCM; Landmark Alzheimer’s approval

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 1

Editors' (re)View: The fate of interchangeability studies; CDMOs and CRLs

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of June 22

Editors' (re)View: Intra-Cellular depression drug nears regulatory submission; Eli Lilly targets counterfeiters

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of June 17

Editors' (re)View: AdComm nod for Lilly Alzheimer's drug; SCOTUS mifepristone decision

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of June 10

Editors' (re)View: Warp speed: The next generation; FDA Adcomm votes against MDMA for PTSD 

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of June 3

Editors' (re)View: Pandemic disagreements; GDUFA research recap

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of May 27

Editors' (re)View: More lawsuits for J&J; Abortion pills as controlled substances

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of May 20

Editors' (re)View: Hot flash treatment space heats up; Alzheimer's resilience

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of May 13

Editors' (re)View: The fate of Emergent's plants; ADC win for Pfizer, Genmab

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 29

Editors' (re)View: McKinsey under fire for opioid crisis; Nexus gives up its generic plant

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 21

Editors' (re)View: A new obesity startup; Schizophrenia treatment happenings

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 15.

Editors' (re)View: Advancing mental health treatment; CMS proposes financial incentives for gene therapy access

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 8

Editors' (re)View: ALS and drug approval criteria; Verve trial paused again

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 1